The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ECOG-ACRIN 5162: A phase II study of osimertinib 160 mg in NSCLC with EGFR exon 20 insertions.
 
Zofia Piotrowska
Consulting or Advisory Role - AstraZeneca; Genentech; Guardant Health; Immunogen; Incyte; Lilly; Medtronic; Spectrum Pharmaceuticals
Research Funding - ARIAD/Takeda (Inst); AstraZeneca (Inst); Guardant Health (Inst); Johnson & Johnson (Inst); Novartis (Inst); Spectrum Pharmaceuticals (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - ARIAD/Takeda; AstraZeneca; Genentech
 
Yating Wang
No Relationships to Disclose
 
Lecia V. Sequist
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Genentech/Roche; Janssen Oncology; Merrimack
Research Funding - AstraZeneca (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Genentech (Inst); Guardant Health (Inst); Incyte (Inst); Johnson & Johnson (Inst); Loxo (Inst); Merck (Inst); Merrimack (Inst); Novartis (Inst); Pfizer (Inst)
 
Suresh S. Ramalingam
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; Lilly/ImClone; Loxo; Merck; Nektar; Takeda; Tesaro
Research Funding - Abbvie (Inst); Advaxis (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Genmab (Inst); Merck (Inst); Merck (Inst); Pfizer (Inst); Takeda (Inst); Vertex (Inst)
Travel, Accommodations, Expenses - AstraZeneca